Sakar Healthcare Peer Comparison

NSE: SAKAR

₹946.50

₹-42.50 (-4.30%)

As on 29-Oct-2026IST

Market cap

₹2,106 Cr

Revenue (TTM)

₹302 Cr

P/E Ratio

49.1

P/B Ratio

6.1

Div. Yield

0 %

Edit

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
Market cap (₹ Cr)	2,106	16,195	6,186	1,723	1,457
Revenue (₹ Cr)	302	3,330	2,289	837	301
Net Profit (₹ Cr)	42.87	720.77	313.25	121.69	45.49
Net Margin (%)	14.09	21.60	12.91	14.35	14.58
RoE (%)	12.79	18.93	12.78	17.79	18.17
Price to Earnings	49.13	22.89	19.75	14.16	32.03
Price-To-Book	6.09	3.91	2.32	2.45	5.98

Income Statement (₹ Cr)

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
Operating Revenue	301.83	3,329.63	2,289.33	837.28	300.76
Total Income	304.33	3,337.47	2,425.61	847.88	311.96
Total Expenditure	211.40	2,168.88	1,923.40	659.64	239.32
EBITDA	90.42	1,160.75	365.93	177.64	61.43
Depreciation	25.45	285.40	60.25	29.63	8.53
EBIT	64.97	875.35	305.68	148.01	52.90
Interest	7.86	187.51	4.34	0.02	1.01
Other Income	2.50	7.84	136.29	10.60	11.21
Exceptional Items	0.00	-53.14	-20.79	0.00	-2.31
Profit before Tax	59.62	642.54	416.84	158.59	60.79
Provision for Tax	16.75	-78.23	103.60	36.90	15.29
Profit after Tax	42.87	720.77	313.25	121.69	45.49

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
Shareholder's Funds	345.99	4,144.34	2,668.91	704.51	243.80
Minority Interest	0.00	-10.85	0.00	0.00	0.00
Non-Current Liabilities	49.82	758.48	73.11	25.50	11.83
Current Liabilities	119.92	2,681.14	433.67	109.56	39.80
Total Liabilities	481.01	7,246.72	3,938.74	853.70	329.30

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
Non-Current Assets	339.65	5,578.78	1,793.21	453.28	95.52
Current Assets	160.59	1,800.86	1,196.99	362.91	165.89
Total Assets	481.01	7,246.72	3,938.74	853.70	329.30
Total Debt*	70.53	2,309.68	0.00	0.00	0.00
Net Current Assets	40.67	-880.28	763.32	253.35	126.10
Contingent Liabilities	--	51.57	204.54	19.86	22.34

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
Cash From Operating Activities	49.26	537.99	200.45	155.77	46.81
Cash Flow from Investing Activities	-28.35	-369.46	-109.93	-181.57	-35.65
Cash from Financing Activities	-20.96	-313.53	-93.33	-3.12	-12.15
Net Cash Inflow / Outflow	-0.05	-145.00	-2.80	-28.91	-0.99

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
ROCE (%)	12.52	14.47	15.93	21.88	22.69
ROE (%)	12.79	18.93	12.78	17.79	18.17
ROA (%)	8.89	9.78	10.34	15.14	15.31
EBIT Margin (%)	21.53	26.29	13.35	17.68	17.59
Net Margin (%)	14.09	21.60	12.91	14.35	14.58
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
Revenue Growth (%)	47.99	11.06	10.20	18.91	6.40
EBIT Growth (%)	119.64	13.71	41.66	101.16	15.67
Net Profit Growth (%)	119.78	60.98	38.96	73.03	-26.56
EPS Growth (%)	117.73	80.38	46.13	94.63	10.27
Book Value Growth (%)	14.81	36.71	8.94	18.33	17.30

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
Price / Earnings	51.33	21.36	18.62	14.59	32.24
Price / Book Value	6.36	3.94	2.30	2.52	6.58
Dividend Yield (%)	0.00	0.00	1.33	0.75	2.40
EV/EBITDA	25.11	15.99	15.33	9.41	22.95
Market Cap (₹ Cr)	1,109.05	17,980.08	5,229.56	1,103.60	1,234.49

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
Debt to Equity	0.10	0.10	0.00	0.00	0.00
Short term debt to equity ratio	0.07	0.12	--	--	--
Current Ratio	1.34	0.67	2.76	3.31	4.17
Quick Ratio	0.53	0.49	2.06	2.11	3.68
Interest Coverage	8.58	4.43	97.11	7,930.50	61.12

	Sakar Healthcare	Eris Lifesciences	FDC	Venus Remedies	Jagsonpal Pharma
Debtors to sales (%)	13.06	18.98	6.71	10.47	8.97
Asset Turnover	0.63	0.45	0.76	1.04	1.01
Receivable days	58.58	63.88	21.28	51.10	18.20
Inventory Days	82.38	43.27	59.64	54.51	17.89
Payable days	107.49	151.85	105.74	96.77	37.27
Cash Conversion Cycle	33.48	-44.70	-24.83	8.84	-1.18

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.